Efinaconazole

Efinaconazole (trade names Jublia and Clenafin) is a triazole antifungal. It is approved for use in Canada, Japan and the United States as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). Efinaconazole acts as a 14α-demethylase inhibitor. Efinaconazole (trade names Jublia and Clenafin) is a triazole antifungal. It is approved for use in Canada, Japan and the United States as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). Efinaconazole acts as a 14α-demethylase inhibitor. In two clinical trials 17.8% and 15.2% of patients using efinaconazole were cured, compared to 3.3% and 5.5% of patients using a placebo. Efinaconazole is not especially effective, but it is currently the best topical treatment available, with cure rates two or three times better than the next best topical treatment, ciclopirox. It is considered a reasonable option for patients with mild cases, or patients who can not take oral treatment. In 2014, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA). According to Valeant Pharmaceuticals International Inc CEO J. Michael Pearson they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008. In 2015 the cost of treatment with efinaconazole in the United States was said to be $2317 per nail.